Bruker timsTOF pro LC-MS system

项目概要_摘要 我们正在申请布鲁克timsTOF Pro捕获离子迁移质谱仪LC- MS系统。该LC-离子迁移率MS系统提供了优于其他系统的上级分辨率 提供更深入的代谢组学、脂质组学和干扰素组学筛选能力， 经典的LC-精确质量MS/MS仪器。随着所要求的 在Bruker timsTOF Pro LC-MS系统中，结构相似的脂质和其他化合物可被 准确地检测和识别。迫切需要这样的系统，以填补未满足的需求， 加州大学戴维斯分校的生物医学界我们已经确定了该仪器的8个主要用户 80%的时间使用，并建议加州大学戴维斯分校代谢组学核心使用20%的时间， 为小用户提供基于充电的项目。 通过提供我们在LC-MS代谢组学方面的基础设施和技术专长，我们计划 与我们的用户进行长期和多样化的合作。所有项目的共同点是 化学复杂性太大，无法通过目前的LC精确质量“在深度”解决 单独MS/MS。用户需要进入下一阶段才能充分解决他们的研究问题。 需要离子迁移率的项目有：环境健康（Young：更深层次的MS/MS 非靶向筛查的覆盖率，货车Winkle：氧化脂质的分辨率更高），癌症 代谢（Carraway：改善了BMP和PG脂质组学的灵敏度和分辨率， 细胞器，陈：提高分辨率的氧甾醇异构体），昼夜周期（邱：解决 同量异位和异构三酰甘油酯），营养干预（斯坦霍普：解决尿 多酚），化合物鉴定方法（Fiehn：提高结构置信度 通过CCS值注释）对肠道微生物组变化的影响（LaSalle： Rett综合征，粪便中生物胺的分解）。所有这些项目都有一个共同点 他们在我们正在进行的合作中遇到了障碍， WCMC目前的仪器缺乏离子迁移率分离的附加能力， 我们在精确质量分析方面的精湛能力。

Project Summary_Abstract We are applying for funds for a Bruker timsTOF Pro trapped ion mobility mass spectrometer LC- MS system. This LC-ion mobility MS systems offers superior resolution to alternative systems providing much deeper metabolomics, lipidomics and exposome screening capabilities than classic LC-accurate mass MS/MS instruments. With the enhanced performance of the requested Bruker timsTOF Pro LC-MS system, structurally similar lipids and other compounds can be accurately detected and identified. Such system is urgently needed to fill gaping unmet needs by the biomedical community here at UC Davis. We have identified 8 major users for this instrument for 80% of time usage and suggest a 20% time usage by the UC Davis metabolomics core to work on recharge-based projects for minor users. By providing our infrastructure and technical expertise on LC-MS metabolomics, we project a diverse and long-term collaborations with our users. The common thread across all projects is that chemical complexities are too large to be resolved ‘in depths’ by current LC-accurate mass MS/MS alone. Users need to get to the next stage to solve their research problems adequately. Projects that need for ion mobility are such as: environmental health (Young: deeper MS/MS coverage for non-targeted screening, van Winkle: higher resolution for oxidized lipids), cancer metabolism (Carraway: improved sensitivity and resolution for BMP and PG lipidomics in organelles, Chen: improved resolution of oxysterol isomers), diurnal cycles (Chiu: resolving isobaric and isomeric triacylglycerides), nutritional interventions (Stanhope: resolving urinary polyphenols), methods in compound identification (Fiehn: improving confidence in structure annotations by CCS values) to gut microbiome changes (LaSalle: interaction of gut-brain axis in Rett syndrome, resolution of biogenic amines in fecal matter). All these projects have in common that they have hit roadblocks in our ongoing collaborations with respect to capabilities of our current instrumentation at the WCMC that lack the added power of ion mobility separation despite our exquisite capabilities in accurate mass analyses.